AbbVie immunology spree continues with $250M Celsius takeout
ImmunotherapyPhase 1License out/inAcquisition
AbbVie on Thursday announced the acquisition of privately held biotech Celsius Therapeutics for $250 million in cash, gaining a potentially first-in-class antibody targeting TREM1 for the treatment of inflammatory bowel disease (IBD).
"Given the potential relevance of TREM1 as a key driver of inflammation and pathology in IBD and other conditions, we are eager to advance the development of CEL383 with a goal of helping more patients with IBD achieve remission," stated Kori Wallace, global head of immunology clinical development at AbbVie.
Sixth immunology deal
The buyout is in line with AbbVie's ongoing efforts to maintain a strong position in immunology, particularly in the wake of its blockbuster Humira (adalimumab) contending with increasing biosimilar competition.
Celsius marks the company's sixth immunology deal so far this year, though not the biggest – that crown goes to its recent licensing agreement for FutureGen Biopharmaceutical's anti-TL1A antibody, also in development for IBD, for up to $1.7 billion. For more see – Spotlight On: AbbVie continues immunology deal streak.
CEL383 recently concluded a Phase I study that got underway last year and assessed safety, tolerability and pharmacokinetics in healthy volunteers. TREM1, expressed on inflammatory monocytes and neutrophils, is seen as a key disease driver in IBD, amplifying inflammation by acting upstream of multiple known inflammatory pathways, the companies said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.